Skip to main content
. 2019 Sep 27;20(19):4812. doi: 10.3390/ijms20194812

Figure 2.

Figure 2

Growth inhibition of lapatinib-resistant breast cancer cells by bortezomib. BT474 and SkBr3 cells and their lapatinib-resistant clones were treated with indicated concentrations of lapatinib and bortezomib for three days and seven days, and were then subjected to cell viability by MTT assay (A–D) and clonogenic assay (E,F), respectively. The concentrations of lapatinib and bortezomib used in the clonogenic assay were 1 μM and 50 nM, respectively. Results are showed as mean ± SD of three independent experiments. p values <0.05, <0.01, and <0.001 are indicated as *, **, and ***, respectively.